Abstract Interleukin (IL)-6 is a potent pro-inflammatory agent that plays a crucial role in the pathogenesis of systemic inflammatory disease. Targeting this pathway in rheumatoid arthritis (RA) seems an attractive option as IL-6 is important for both joint destruction and systemic manifestations. Currently, tocilizumab, which binds the IL-6 receptor, is licensed for treatment in active, moderate to severe disease in RA and systemic juvenile idiopathic arthritis (JIA). Several other promising IL-6 blocking agents as well as a subcutaneous form of tocilizumab are currently undergoing phase III clinical trials. The aim of this article is to provide an up-to-date analysis of clinical efficacy and tolerability data concerning the use of IL-6 inhibitors. Data from clinical trials demonstrated that clinical efficacy for tocilizumab, which included improvement in physical function and halting radiographic progression, were comparable to other biologics licensed for use in RA. Patients who should gain most are RA patients with systemic features such as high inflammatory markers and anaemia. Perhaps, the strongest selling point lies in its effectiveness as a monotherapy. This is particularly useful in those who are not tolerating combination treatment with methotrexate. Tocilizumab is one of a few biologics that have been shown to be superior to methotrexate in head-to-head studies. The safety profile of tocilizumab also is comparable to other currently available biologics. There is a small but significant increase in adverse events including infections in patients treated with tocilizumab compared to placebo, particularly in patients who are elderly and those with multiple comorbidities. Elevated lipid profiles are frequent but have not been associated with major cardiovascular events. IL-6 blockade is a major advancement in the treatment of RA as it targets a unique molecule. Over the next few years, evidence will be available on the long-term cardiovascular safety and efficacy of subcutaneous IL-6 blocking agents.
Introduction
Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease characterised by symmetrical persistent synovitis affecting multiple predominantly small joints. The disease also leads to fatigue, pain and other extraarticular manifestations. It is a common disease with a prevalence of 1 % worldwide [1] . If left untreated, it will lead to significant joint destruction, reduced mobility and increases the healthcare burden.
Since the introduction of the concept of early intervention in the early 1990s [2] , the management of our rheumatoid patients has shifted to a new paradigm. Rheumatologists have become more proactive in identifying patients presenting with early inflammatory arthritis symptoms and now treat them aggressively with the aim of rendering the disease into remission at the earliest opportunity. Thus, fewer RA patients are seen with significant deformity these days.
Our understanding of the pathophysiology of RA has also improved with an understanding of the various pathways of the cytokines that drive the inflammatory cascades. These include the role of tumour necrosis factor (TNF), interleukin (IL)-1 and IL-6, as well as the role of B and T cells. As a result, we have various options in treating our patients from the use of conventional synthetic Disease Modifying AntiRheumatic Drugs (DMARDs) to the different biologics, which include TNF inhibitors such as infliximab, etanercept, adalimumab, golimumab and certolizumab, rituximab (monoclonal anti-CD-20 providing B-cell depletion), anakinra (IL-1 inhibitor) and abatacept (T-cell co-stimulatory inhibitor).
Despite the wealth of different biologics, combination treatment using DMARDs and biologics often raises safety issues. More importantly, there is a lack of headto-head success in regards to superiority of the biologics given as monotherapy against methotrexate [3] [4] [5] . Even when a TNF inhibitor is given in combination with DMARDs, the rate of inadequate response has been quoted as about 20-40 % in various populations studied [6] , prompting the clinician to switch to a different form of biologic. One novel treatment that shows promising results is targeting IL-6, which plays a pivotal role in the inflammatory cascade and also halts radiographic structural progression. The aim of this article is to provide a detailed critical analysis of clinical efficacy and tolerability data concerning the use of IL-6 inhibitors. We will conclude with our expert opinion on the place of IL-6 inhibitors in the treatment of RA.
To achieve these objectives, a literature review of the published literature in the English language concerning the clinical efficacy and safety of IL-6 inhibitors in RA was first undertaken using PubMed, Embase and Cochrane Library databases up to November 2012. The keywords searched included 'biologics', 'interleukin-6', 'tocilizumab' and 'rheumatoid arthritis'. Abstracts presented from 2008 to 2012 at the American College of Rheumatology (ACR) and European League against Rheumatism (EULAR) conferences were searched. Lastly, clinical trials that were registered in the national registries were also sought.
The Role of Interleukin (IL)-6 in the Pathogenesis of Rheumatoid Arthritis
IL-6 is a pleiotropic cytokine, a 26-kDa glycopeptide encoded on chromosome 7. It is produced by various cell types such as T cells, B cells, monocytes, fibroblasts, osteoblasts, keratinocytes, endothelial cells, mesangial cells and some tumour cells [7] . IL-6 can activate cells through two signalling pathways; the first is the membranebound receptor (mIL-6R) via activation of glycoprotein (gp) 130 and the second is via proteolytic cleavage of the mIL-6R that leads to the generation of a soluble receptor for IL-6 (sIL-6R) [8, 9] . The binding of IL-6 to sIL-6R enables the stimulation of cells that lack endogenous soluble receptors, thus widening the number of cell types responsive to this cytokine [10, 11] .
In relation to the pathogenesis of rheumatoid arthritis, IL-6 plays a role in adaptive immunity. IL-6 stimulates B cells to differentiate into plasma cells, which produce immunoglobulin [12] . It also influences T-cell development by stimulating the proliferation and differentiation of T lymphocytes into T-helper (Th)-17 cells, which produce IL-17. In vitro studies in mice have shown that the co-stimulation of IL-6 and transforming growth factor (TGF)-b is essential for the differentiation of Th-17 cells from naive CD4? T cells [13, 14] .
Excess production of IL-6 has been found in the synovial fluid and blood of RA patients and correlates with the disease activity and joint destruction [15, 16] . IL-6 promotes synovitis by inducing neovascularisation via vascular endothelial growth factor (VEGF)-stimulated pannus proliferation, resulting in infiltration of inflammatory cells and synovial hyperplasia [17] . In terms of joint erosion, IL-6 causes bone resorption by inducing osteoclast formation via the induction of RANKL in synovial cells [18, 19] and cartilage degeneration by producing matrix metalloproteinases (MMPs) in synovial cells and chondrocytes [20, 21] .
In addition, this cytokine is responsible for mediating many of the systemic manifestations of RA. It induces the acute-phase response, particularly the development of C-reactive protein (CRP), fatigue via the hypothalamicpituitary-adrenal (HPA) axis [22] and osteoporosis from its effect on osteoclasts. IL-6 also affects a change in lipid concentrations in blood. Furthermore, it induces the production of hepcidin, which is responsible for anaemia of chronic inflammation [23] . Thus, IL-6 is a pleiotropic cytokine and a suitable target in the treatment of RA.
Tocilizumab and Other IL-6 Agents Currently Under Development
Tocilizumab, a humanised anti-IL-6R antibody, prevents IL-6 from binding to both mIL-6R and sIL-6R, thereby blocking the pro-inflammatory effects of IL-6. Its molecular weight is *150 kDa [24] . It binds to sIL-6R in a dosedependent manner and saturates the receptor at *0.1 lg/ ml. It also competitively inhibits IL-6 binding to sIL-6R, with complete inhibition seen at *4 lg/ml [10] . Tocilizumab was initially developed by a collaborative effort between Osaka University and the Chugai Pharmaceutical Co. (Ltd.), Japan, a subsidiary of HoffmanLaRoche [25] . In Europe and the rest of the world, it is given intravenously at a dose of 8 mg/kg every 4 weeks. The subcutaneous formulation (162 mg weekly) is now entering phase III trials and the preliminary data have shown comparable efficacy and safety profiles to the established intravenous formulation [26] . In the US, the recommended starting dose for RA is 4 mg/kg, followed by an increase to 8 mg/kg based on the clinical response. Starting at the lower dose may not be ideal because of its insufficient efficacy in delaying remission, a higher risk of anaphylactic reactions and increased risk of immunogenicity [27] .
Currently, the use of tocilizumab is licenced for the treatment of RA and systemic juvenile idiopathic arthritis (JIA). A recent consensus indicated that tocilizumab can be used in adult patients with active RA, normally with at least moderate disease activity according to a validated composite measure, who have had an inadequate response to, or intolerance of at least one synthetic DMARD and/or a TNF inhibitor [28] . In 2012, both the National Institute for Health and Clinical Excellence (NICE) of the UK and the Food and Drug Administration (FDA) agency of the US expanded the approved indication of tocilizumab to be used as a ''first-line biological agent'' in RA patients who have had an inadequate response to one or more synthetic DMARDs.
In Japan, it is also licensed for use in the treatment of Castleman's disease [29] . There are also case reports in regards to the use of tocilizumab in other autoimmune conditions such as giant cell arteritis [30, 31] , adult onset Still's disease [32] , systemic lupus erythematosus [33] , anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis [34] , Behcet's disease [35, 36] , systemic sclerosis [37] and polymyositis [38] . These reports showed that tocilizumab was the salvage therapy used after disease resistance to various former drugs. More open-labelled or randomised controlled trials are needed to explore these in the future.
There are four other IL-6 agents that are currently under development, three of which are now entering phase III studies as summarised in Table 1 . All but one of these agents are administered as subcutaneous formulations. Sarilumab is the first fully human monoclonal antibody directed against IL6Ra. The MOBILITY study, a phase II double-blind, multinational trial, recruited 306 adults with active, moderate-tosevere RA who did not respond adequately to methotrexate [39] . Patients were randomised into six groups: sarilumab 100 mg 2-weekly, 150 mg 2-weekly, 100 mg weekly, 200 mg 2-weekly, 150 mg 2-weekly or placebo (all in combination with methotrexate). The results showed that the primary outcome, American College of Rheumatology (ACR20) response, was met at 12 weeks and was significant versus placebo (p = 0.02) in the 150 mg every 2-weekly sarilumab arm, 72.0 versus 46.2 %. The types and incidence of adverse events (AEs) were comparable to other IL-6 inhibitors.
BMS945429, a humanised monoclonal antibody that potently binds IL-6, completed a phase II double-blind randomised placebo-controlled trial [40] . One hundred and twenty-seven patients who did not respond adequately to methotrexate were randomised to 1:1:1:1 to BMS945429 (80, 160 or 320 mg; administered intravenously) or placebo plus methotrexate. At week 12, the primary endpoint in the form of ACR20 response was achieved in 81 % (80 mg; p \ 0.0001 vs. placebo), 71 % (160 mg; p = 0.0005 vs. placebo), 82 % (320 mg; p \ 0.0001 vs. placebo) and 27 % (placebo). The disease activity score according to the 28-joint remission criteria (DAS-28 \2.6) was also achieved at week 16 in 14 % (80 mg), 28 % (160 mg) and 44 % (320 mg) of the BMS945429 groups. The other secondary endpoint, clinical improvements in health-related quality of life (HRQoL), was also statistically significant in the treatment groups.
Sirukumab is a humanised monoclonal antibody against the sIL-6R. It is administered subcutaneously. In the second part of the proof of concept phase II randomised controlled study, the investigators recruited 151 RA patients who did not respond adequately to methotrexate. The patients were randomised equally to five treatment arms: (1) placebo from week 0-10 followed by sirukumab 100 mg every 2-weekly from week 12-24, (2) sirukumab 100 mg every 2-weekly from week 0-24, (3) sirukumab 100 mg every 4-weekly from week 0-24, (4) sirukumab 50 mg every 4-weekly from week 0-24 and (5) sirukumab 25 mg every 4-weekly from week 0-24 [41] . At week 12, all of the sirukumab arms (in combination) significantly improved ACR50 response (overall p = 0.010) and significantly reduced the DAS-28 scores from baseline (p \ 0.001) compared to placebo. The patients who received sirukumab 100 mg every 2-weekly achieved the highest remission rates based on DAS-28 and simplified disease activity index (SDAI) criteria throughout the study up to week 24.
The other novel IL-6 blocking agent that is currently under development is olokizumab. It selectively blocks the final assembly of the IL-6 signaling complex (gp80 ? gp130 ? IL-6) [42] . A recent double-blind, placebo-controlled pilot study recruited 40 RA patients who were on a stable dose of methotrexate but with a high CRP. They were randomised to a single dose of olokizumab, either (0.1 or 1.0 mg/kg intravenously) or (1.0 or 3.0 mg/kg subcutaneously), or a placebo. At 12 weeks, the results showed that regardless of the dose or route of administration, a single dose of olokizumab demonstrated prolonged suppression of CRP. However, the CRP level in the 0.1 mg/kg intravenous group showed some recovery after 28 days. Importantly, all doses were well tolerated. The clinical efficacy and long-term tolerability of olokizumab will be explored further in phase II trials that are currently recruiting patients.
Clinical Efficacy
The use of IL6 inhibitors has been tested in multiple large randomised controlled trials. So far, only tocilizumab is licensed and will be the focus for this discussion. Ten pivotal trials are elaborated here and summarised in Table 2 . Although the study protocols are different, the Table 1 Interleukin-6 blocking agents other than intravenous tocilizumab currently under development Drugs Tocilizumab [26] Sarilumab [39] BMS945429 [40] Sirukumab [41] Olokizumab [42] Pharmacology description IL-6 receptor monoclonal antibody that binds to both soluble and membranebound receptor IL-6 receptor monoclonal antibody that binds to the alpha subunit of the IL-6 receptor complex 
Tocilizumab Monotherapy
The earliest phase II double-blind placebo-controlled study was conducted by Nishimoto and colleagues [43] in 2004.
At that time, tocilizumab was known as MRA. In this multicentre study conducted in Japan, 164 patients with refractory RA were randomised to receive either MRA (4 mg/kg body weight or 8 mg/kg body weight) or placebo. MRA was given as monotherapy as all DMARDs were withdrawn prior to the study. The primary endpoint was the ACR20 response while secondary endpoints included the ACR50 and ACR70 responses, the DAS-28 responses and the safety profiles at 18 weeks. The results showed that at 3 months, 78 % of patients in the 8 mg/kg group, 57 % in the 4 mg/kg group and 11 % in the placebo group achieved at least a 20 % improvement in disease activity according to the ACR criteria (p \ 0.001 for 8 mg/kg group versus placebo). The secondary endpoints were all met with significant results versus the placebo, particularly in the 8 mg/kg monotherapy group. Most importantly, MRA was well tolerated; the incidence of AEs (mostly were mild) was 56, 59 and 51 % in the placebo, 4 mg/kg and 8 mg/kg groups respectively, and these were not dose dependent. An increase in blood cholesterol was observed in 44.0 % of the patients treated with MRA, although no cardiovascular complications were observed. These positive findings in terms of clinical efficacy and tolerability have stimulated other phase III studies examining the use of tocilizumab monotherapy. The AMBITION (Actemra versus Methotrexate doubleBlind Investigative Trial In mONotherapy) study recruited 673 patients with different selection criteria. Of these patients, 67 % were methotrexate-naïve at baseline, whereas patients who had previously failed either methotrexate or a TNF inhibitor were excluded [44] . There were three arms in which patients were randomised to either an escalating dose of methotrexate or tocilizumab 8 mg/kg, with a separate sub-study (n = 101) recruiting patients to placebo for 8 weeks followed by active treatment. The primary endpoint was the ACR20 response at 24 weeks. The results showed non-inferiority and in fact superiority of toclizumab versus methotrexate. The weighted difference for ACR20 response at week 24 was 0.19 (95 % CI 0.11-0.27, p \ 0.001). A significant difference was evident as early as week 2. The superiority was also true in the methotrexate-naïve patients in the sub-analysis. Other secondary endpoints include the ACR50 and ACR70 responses, remission in the form of DAS-28 \2.6, achievement of moderate EULAR response and HAQ-DI from baseline, which also demonstrated superiority of tocilizumab against methotrexate. Fungal infections were more common in the methotrexate group. Four deaths occurred during the study, three in the tocilizumab arm, of which one was thought remotely related to treatment (gastrointestinal haemorrhage).
The SATORI study recruited 127 patients with an inadequate response to methotrexate [45] . This doubleblind Japanese study randomised patients to either tocilizumab 8 mg/kg or to methotrexate 8 mg per week. The dose of methotrexate is notably low in this study, in keeping with current practice then in Japan. Nearly half of the participants from the control group (48 %) withdrew from the study, mainly because of a poor response to the treatment. The primary outcome was achieved with 80 % of tocilizumab-treated patients compared to 25 % of control patients achieving the ACR20 response at week 24. Serum VEGF levels decreased significantly more in the tocilizumab group than in the control group. No significant difference was seen in the number of patients discontinuing the study because of AEs. Nasopharyngitis was seen slightly more frequently in the tocilizumab group.
The ACT-RAY is the only double-blind phase III study that assessed the efficacy and safety profile by either adding tocilizumab to methotrexate strategy or switching methotrexate to tocilizumab monotherapy. This was done over a 2-year period in patients who had an inadequate response to methotrexate. The results are now available at 52 weeks [46] . A total of 556 patients were randomly assigned to either continue methotrexate with the addition of tocilizumab 8 mg/kg 4-weekly or switch to tocilizumab monotherapy. The primary endpoint was the clinical remission rate in the form of DAS-28 at week 52 while the secondary endpoints included other symptomatic outcomes such as ACR responses, HAQ-DI and progression of structural damage using GSS. The results showed that the DAS-28-erythrocyte sedimentation rate (ESR) remission rate was significant in the add-on group compared to the switch to monotherapy group, 45.5 and 36.6 % respectively (p = 0.03). Although all other secondary endpoints showed improvements in both groups, which was maintained throughout up to week 52, there was no statistically significant superiority of the add-on strategy against the switch to monotherapy strategy in all other composite measures. The majority of the structural progression from baseline was arrested. However, significantly more switch patients experienced radiographic progression than in the add-on group. The rates of AEs and serious infections were also comparable. The only different but important safety issue was that treatment in combination with methotrexate resulted in a higher rate of abnormal liver transaminases (greater than 3 times the upper limit of normal [ULN]) than the monotherapy group, 11 versus 3 %. This laboratory abnormality has been a consistent finding from week 28 up to week 52.
The SAMURAI (Study of Active controlled Monotherapy Used for Rheumatoid Arthritis, an IL-6 inhibitor) study was a Japanese open-label but radiograph readerblinded study to examine primarily the effect of tocilizumab monotherapy on radiographic progression based on van der Heijde-modified Sharp score (vdH-Sharp score) at 52 weeks [47] . Three hundred and six patients were randomised to either an 8-mg/kg dose of tocilizumab monotherapy group or DMARDs (mostly combination DMARD therapy including low-dose methotrexate). In terms of clinical efficacy, the secondary endpoints showed the superiority of tocilizumab monotherapy against the conventional DMARDs therapy (p \ 0.001) for each of the ACR response components, although this was assessed unblinded. Clinical remission defined as DAS-28 \2.6 was achieved in 59 % of patients receiving tocilizumab compared to only 3 % of patients receiving DMARDs (p \ 0.001).
In terms of long-term clinical efficacy, the STREAM (Long-term Safety and efficacy of Tocilizumab, an anti-IL-6 REceptor monoclonal Antibody, Monotherapy, in patients with rheumatoid arthritis) study is the longest to date, with 5-year follow-up duration, that assessed the safety and clinical efficacy [48] . This is an extension trial that was carried out by Nishimoto and colleagues [43] described earlier in this article although the difference is that it is an open-label study after the initial double-blind trial. Of the 143 patients, 66 % completed the 5-year study. Notably, the response rate according to the ACR improvement criteria increased during the initial year and subsequently remained constant throughout the study period. At 5 years, 84.0, 69.1 and 43.6 % of the tocilizumab group achieved the ACR20, ACR50 and ACR70 responses respectively. In fact, improvement in all other parameters, including tender joint counts, swollen joint counts, CRP levels, HAQ score and clinical remission (DAS-28 \2.6), from the earlier phase II study was sustained throughout the 5-year follow-up. Only one patient withdrew because of lack of response while 22 % withdrew because of AEs. [49] . All other DMARDs and biologics were discontinued prior to the start of the study. The primary endpoint was the ACR20 response at 24 weeks. The secondary endpoints included ACR50 and ACR70 responses at 24 weeks, the DAS-28 response and HAQ-DI to assess physical functionality. The patients were randomised to tocilizumab 4 mg/kg, 8 mg/kg or placebo each with methotrexate at a stable dose. The results showed that at 24 weeks, the ACR20 was achieved by 48 % of patients allocated to tocilizumab 4 mg/kg, 59 % of patients receiving 8 mg/kg dose tocilizumab and 26 % of patients in the placebo group (p \ 0.0001). A significantly greater number of patients receiving tocilizumab showed ACR50 and ACR70 responses and DAS-28 remission (DAS-28\2.6) at week 24 than did those in the placebo groups.
The ROSE (Rapid Onset and Systemic Efficacy) study was the first phase IIIb study that recruited 619 patients from various centres only in the USA who had an inadequate response to DMARDs (DMARDs-IR) [50] . Prior use of other biologics was permitted but they were subsequently withdrawn before randomisation. Patients were randomised on a 2:1 basis to tocilizumab 8 mg/kg or placebo while continuing stable background DMARDs therapy. The primary endpoint was the ACR50 response at week 24. The secondary endpoints included the ACR20 and ACR70 responses, the DAS-28 response and the EULAR response at 24 weeks. The results showed that the ACR50 response at week 24 was significantly higher in the tocilizumab group than in the placebo group (30.1 vs. 11.2 %; p \ 0.0001). A significantly greater number of patients receiving tocilizumab achieved the ACR20 and ACR70 responses and the EULAR good response at all time points starting from week 4 and clinical remission (DAS-28 \2.6) at week 24 compared to the placebo group. A sub-study examining early response to therapy was also undertaken and showed improved patient's global assessment of disease activity, pain, CRP and ESR in the tocilizumab group compared to placebo as early as day 7, but not in the swollen or tender joint counts and physician's global assessment.
Of all the phase III studies, TOWARD (TOcilizumab With traditional DMARD) recruited the largest patient population, 1,220 patients worldwide [51] . The patients were randomised in a 2:1 manner to either tocilizumab 8 mg/kg or placebo along with stable doses of DMARD therapy throughout. It is the only study that exclusively excluded prior treatment with biologics. The primary endpoint was the ACR20 response at 24 weeks. The results showed that in the tocilizumab group, 61 % of patients met the primary endpoint compared to 25 % in the placebo group. The improvement in the ACR response was consistent across the various types and numbers of DMARDs used with the exception of patients receiving at least three DMARDs in combination. All other secondary endpoints were also achieved, notably the ACR50 and ACR70 responses, which were apparent from week 4 and continued to week 24. AEs were reported more in the tocilizumab group than in the control group (73 vs. 61 %), although withdrawals from the study because of AEs were infrequent. There was not a clear difference in serious infections. As the participant numbers are large, this study adds to the evidence of efficacy and relative safety of tocilizumab in combination with any other DMARDs available.
The RADIATE (Research on Actemra Determining EffIcacy after Anti-TNF FailurEs) study is the only phase III multicentre placebo-controlled trial that recruited only patients who had previously failed TNF inhibitors (TNF-IR) [6] . A total of 499 patients from North America and Europe were randomised to tocilizumab at a dose of 8 mg/ kg, 4 mg/kg or placebo along with a combination of methotrexate. Nearly half the patients had failed one TNF inhibitor, 38 % had failed two agents and 14 % had failed at least three. The primary endpoint was the ACR20 response at week 24, while the secondary endpoints included the ACR50 and ACR70 responses, the DAS-28 response and also the EULAR response. The results showed that both the 8 mg/kg (50.0 %) and the 4 mg/kg (30.4 %) group exhibited superior ACR20 responses compared with control (10.1 %; p \ 0.001). Significant ACR50 and ACR70 responses as well as EULAR responses were met in both groups receiving tocilizumab. However, the 8 mg/kg tocilizumab was notably superior compared to the 4 mg/kg group in terms of clinical DAS-28 remission. Interestingly, there was no definite relationship between the ACR response rates and the number or type of prior TNF inhibitors.
The LITHE study was a double-blind randomised controlled trial with the longest follow-up, 52 weeks [52] . A total of 1,196 patients from 15 countries were recruited and randomised to three arms: tocilizumab 8 mg/kg, 4 mg/kg or placebo, all in combination with methotrexate. Prior TNF inhibitor therapy was allowed. A rescue therapy of tocilizumab 4 mg/kg was offered to the patients who did not experience 20 % improvement in terms of tender and swollen joint counts by week 16. The two primary endpoints were the change from baseline in the radiographic score using GSS and change in physical function using HAQ-DI at week 52. By the end of the study period, half of the control group had received rescue treatment. Both primary outcomes were met, with a 74 and 70 % reduction in radiographic progression in the tocilizumab 8 mg/kg and 4 mg/kg groups respectively. HAQ-DI improvement was also significant in the treatment groups compared to the placebo groups. Other efficacy analysis also showed that the ACR responses were greatest in the tocilizumab 8 mg/ kg group. No apparent differences were seen in exposureadjusted rates of serious AEs between the tocilizumab and placebo groups.
Composite Index Without Using Acute Phase Reactants as Measurement of Clinical Efficacy
Most composite indices, such as the ACR improvement criteria, DAS-28 and SDAI, include either CRP or ESR in the formula. Although it has been reported that the degree to which acute phase reactants (APR) contribute to the constituent elements of the DAS-28 is no more than 15 % [53] , there is always a theoretical assumption that these composite indexes may overestimate the clinical response in patients treated with an IL-6 inhibitor, particularly in terms of the definition of remission [54] . This is particularly true as the CRP production is induced mainly or not exclusively by the IL-6 cytokine, although the TNF and IL-1 cytokines have also indirect roles in the mediation [55, 56] . In order to tackle this, the Clinical Disease Activity Index (CDAI), an index that has been validated previously in assessing the severity of RA was studied as it does not include APRs [57, 58] . The formula for calculation is CDAI = TJC ? SJC ? GH ? EGA, where TJC = tender joint count (0-28), SJC = swollen joint count (0-28), GH = patient's assessment of general health (cm) and EGA = physician's global assessment (cm). The cutoff points are: Remission (CDAI B2.8), Low Disease Activity (CDAI between 2.8 and 10), Moderate Disease Activity (CDAI between 10 and 22) and High Disease Activity (CDAI [22) .
Kaneko and colleagues [59] recruited 31 patients who were DMARD-IR or TNF-IR, treated with tocilizumab 8 mg/kg. The length of follow-up was 52 weeks. The results showed that mean baseline DAS-28-ESR was 5.96, decreasing to 2.89 at week 52 with a remission rate (DAS-28-ESR \2.6) of 35.5 %. On the other hand, the mean baseline of CDAI was 28.4, falling to 10.2 at week 52, with a remission rate (CDAI B2.8) of 22.6 %. Further analysis also showed that of patients whose CRP levels were not detected by week 12, 65.2 % achieved remission or low disease activity as assessed by CDAI at week 52.
On a larger scale, Smolen and Aletaha [60] obtained results from a random sample of 80 % of patients from the three randomised clinical trials (LITHE, OPTION and TOWARD) and pooled the results. The patients were mainly DMARD-IR and not methotrexate-naïve or TNF-IR. The results showed that in patients treated with tocilizumab, the reduction in disease activity is statistically significant against the placebo irrespective of the type of composite measures used to evaluate disease activity. The remission rates in the tocilizumab groups were much higher using the DAS-28 compared to SDAI and CDAI, 30 % against 7.7 % and 6.4 % respectively. This can be explained by the high weight of the ESR in the DAS-28 calculation and the effect of tocilizumab on repressing the APR. Using the CDAI index, the remission rates in patients treated with tocilizumab were similar in magnitude to those treated with TNF inhibitors.
Effect on Radiographic Progression
Osteoclasts are the key cells involved in mediating erosions in inflammatory arthritis. Osteoclastogenesis occurs from the interaction between receptor activator of nuclear factor (NF)-jB (RANK) and its ligand (RANKL) [61, 62] . In a neonatal mouse calvaria experiment, IL-6 in the presence of sIL-6R, enhanced the expression of RANKL and osteoprotegerin (OPG), thus inducing bone resorption [19] . However, the RANK expression was also found to be decreased, suggesting that sIL-6R trans-signalling influences osteoclastogenesis through osteoblast and osteoclast interaction.
Applying this animal study finding to the human trials, both the LITHE and ACT-RAY trials showed that tocilizumab retarded the structural disease progression using the GSS. In the LITHE study, progression of structural damage from baseline to week 52 was reduced by 74 and 70 % with tocilizumab 8 mg/kg and 4 mg/kg, both in combination with methotrexate, respectively, as compared with controls (p \ 0.0001) [52] . The ACT-RAY study compared the effect on radiographic progression between two groups, tocilizumab monotherapy and tocilizumab ? methotrexate. The radiographic progression was defined as any change in GSS [ the smallest detectable change (SDC) computed based on the difference between the X-ray readers. The results showed that the overall radiographic progression was small in both groups, although it was statistically significant (add-on therapy versus switch to monotherapy), 8 and 14 % respectively [46] .
The SAMURAI study assessed the radiographic progression between tocilizumab 8 mg/kg monotherapy and DMARDs-only groups based on a different scoring system, the vdH-Sharp score at 52 weeks. The results showed 56 % of patients receiving tocilizumab had no radiographic progression [i.e change from baseline in the total Sharp Score (TSS) B0.5 compared with 39 % of patients receiving conventional DMARDs (p \ 0.01)] [47] . In addition, the erosion scores and joint space narrowing scores also showed significantly less change in the tocilizumab group than in the DMARD group.
Recently, studies exploring the structural progression using magnetic resonance imaging (MRI) are under way. Results from 12 weeks of study showed that treatment with tocilizumab is associated with early suppression of synovitis and osteitis, with no mean increase in the erosion score [63] . There was no statistical difference between tocilizumab monotherapy and in combination with methotrexate.
Other Clinical Efficacy
Treatment with tocilizumab also increases the haemoglobin level in various phase III studies whether it is administered as a monotherapy or in combination with other conventional DMARDs. In the STREAM study, most patients exhibited anaemia at baseline and the mean (±SD) haemoglobin level was 11.3 ± 1.4 mg/dl [48] . After 5-year follow-up, treatment with tocilizumab significantly improved anaemia in these patients and the mean haemoglobin level increased to 13.2 ± 1.5 mg/dl (SD 1.5). The AMBITION study also indicated that the improvement in haemoglobin levels was seen as early as week 2 with normalisation of mean haemoglobin by week 6 and subsequently maintained through to week 24 [44] .
The HAQ-DI is designed to assess the patient's usual abilities and physical function. It is composed of 20 items from eight different categories. The HAQ-DI is sensitive to change and is a good predictor of future disability and costs [64, 65] . Again, various tocilizumab trials showed improvement of HAQ-DI from baseline. In the LITHE study, at 52 weeks, ANOVA of the adjusted mean area under curve (AUC) of the change in the HAQ-DI score from baseline showed a significantly greater decrease in the tocilizumab 8-mg/kg and 4-mg/kg plus methotrexate groups (-144.1 and -128.4 units, respectively) than in the control group taking placebo plus MTX (-58.1 units; p \ 0.0001 for both comparisons) [52] .
Safety Profile
In an analysis of cumulative safety data from five pivotal phase III trials and two extension trials, two populations were studied. The first group included patients randomised to the different treatment arms during the controlled portions of the studies, followed until the first change in treatment regimen or until 2 years of treatment (n = 4,199, controlled population). The second group comprised those who were exposed to at least one dose of tocilizumab (n = 4,009, all-exposed population) [66] . The analysis, which had a mean treatment duration of 2.4 years, confirmed that the long-term safety profile of tocilizumab was comparable to that observed in the phase III studies (duration up to 1 year).
The overall rate of AEs was 339.0/100 patient years (PY) in the control group, 358.0/100 PY in the tocilizumab 4-mg/kg group and 381.6/100 PY in the tocilizumab 8-mg/ kg group in the all-controlled population group. In the allexposed groups, the rate of AEs was 278.2/100 PY in which elevated transaminases levels and infections were the commonest AEs reported. The rate of serious AEs (SAEs) was not different between the groups and did not increase with prolonged exposure. In fact, the rates of SAEs, including deaths, were similar to those observed in other biologics clinical trials in RA although direct comparison as always may not be accurate as different study protocol and designs were employed.
Infections
In the all-exposed population, the rates of serious infections were the highest in the tocilizumab 8-mg/kg group compared to the tocilizumab 4-mg/kg group and the control group, 4.9/100 PY, 3.5/100 PY and 3.5/100 PY respectively. Regardless of the different exposed groups, serious infection cases were attributed to other confounding factors such as patient's pre-existing pulmonary disease, diabetes, older age, high body mass index, concomitant corticosteroids or prior treatment with a TNF inhibitor [66] . Skin and respiratory tract infections were commonly reported. Seven cases of tuberculosis were reported in the all-exposed group, although it was uncertain whether these were new cases or cases in which the initial screening for latent tuberculosis was inadequate. One report of leukoencephalopathy [67] was associated with tocilizumab, while one fatal case of reactivation of hepatitis B virus infection was reported by Nishimoto et al. 43] . Notably, similar to SAEs, the rate of serious infections was stable over time.
In another meta-analysis of six randomised controlled trials, four of which were again included in the analysis (RADIATE, OPTION, TOWARD and AMBITION), after excluding the CHARISMA study because of the small number of subjects, the authors found that combination treatment with tocilizumab 8 mg/kg and methotrexate resulted in a greater risk of serious infection when compared with controls (odds ratio [OR] = 1.78; 95 % CI 0.98-3.23) [68] . However, this is a lesser risk than with TNF inhibitors, as a meta-analysis of harmful effects in randomised controlled trials involving anti-TNF inhibitor therapy concluded that the pooled OR for serious infection in comparison with controls was 2.0 (95 % CI 1.3, 3.1) [69] . Direct comparison should be carefully interpreted though. The TOWARD trial reported opportunistic infection as one patient was diagnosed with Mycobacterium avium intracellulare after being found to have an abnormality on a chest radiograph [51] . The main safety profiles are summarised in Table 3 .
Laboratory Abnormalities
Elevated levels of hepatic transaminases (ALT and AST) were observed in about one third of the tocilizumab-treated patients. The increment was generally mild and reversible. An increment in ALT particularly more than 3 9 the ULN in patients treated with tocilizumab was less common with tocilizumab monotherapy [66] . Importantly, no association between liver enzyme elevation and clinically apparent drug-induced liver injury was demonstrated. Of the 11 liver biopsy samples that were done, only 9 steatohepatitis cases were present in which the patients also had other risk factors such as obesity and diabetes [44, 66] .
Neutropenia, largely due to migration of neutrophils [70] , was commonly reported in patients treated with tocilizumab. Generally, this was not associated with an increased risk of infections. In the all-exposed population, 32 patients had thrombocytopenia of either grade 3 or grade 4 in which one was reported to have a serious bleeding event (haemorrhagic stomatitis) [66] . The infusion was maintained and the event subsequently resolved without further complication. Temporary thrombocytopenia resulted from the decrease in IL-6 after starting tocilizumab as thrombocytosis is mediated by IL-6 [28] .
Alteration in lipid profiles was also linked to treatment with tocilizumab. A possible explanation is that active RA is associated with lowering of the serum cholesterol and low-density lipoprotein levels; thus treatment with tocilizumab returns these levels to what would be 'normal' for that patient [71] [72] [73] . On a positive note, the STREAM study found no evidence of an increased risk of cardiovascular disease at 5-year follow-up [48] . Furthermore, the rates of myocardial infarctions and strokes were similar in the tocilizumab treatment groups and the control group and did not increase over time. The main laboratory abnormalities are summarised in Table 4 .
Malignancy
The overall rate of solid malignancy in the all-exposed group was 1.1/100 PY and was stable even after prolonged exposure [66] . This is comparable to other biologic treatments. For instance, in a large contemporary US cohort of RA patients, the rate of malignancy was 1.3/100 PY, of which 62 % were treated with TNF inhibitors [74] . Interestingly, in animal studies, IL-6 appears to have tumourpromoting activity and targeting IL-6 pathways may be effective in some cancers [75, 76] . However, this needs to be translated into human observational studies.
Other Safety Profiles
Clinically significant hypersensitivity reactions were reported in about 1 % of patients and occurred mainly within the first four infusions [66] . Anaphylactic reaction was more common in the toclizumab 4 mg/kg group than in the 8 mg/kg group [28] . Antibodies to tocilizumab occurred in about 2-4 % of the patients, although this did not seem to predispose the hypersensitivity reactions [28] .
The rate of gastrointestinal perforations was 0.28/100 PY in the all-exposed group [66] . The majority of these patients had a history of diverticulitis and concurrent use of NSAIDs or corticosteroids which put them at further risk.
Recent evidence has suggested that TNF inhibitors are associated with the development of demyelinating disease [77, 78] . It is still uncertain whether this is also the case with tocilizumab treatment. Until data are widely available, caution needs to be taken in prescribing tocilizumab, (7) 24 (6) 7 (1.8)
56 (14) 53 (14) TCZ 8 mg/kg 36 (9) 40 (10) 17 (4.3)
102 (26) 70 ( The author used 6.2 mmol/l as the cutoff point, which is equivalent to 250 mg/dl particularly in patients with pre-existing disease and in patients with a positive family history of demyelinating disease [28] .
Expert Opinion
The value of blocking IL-6 lies in its versatility in neutralising various cytokine pathways responsible for immune regulation, haematopoiesis and inflammation. IL-6 is a potent pro-inflammatory agent that induces fever, fatigue and many other clinical attributes associated with inflammation. Thus, blocking the IL-6 pathway has proven popular in recent times in treating systemic inflammatory disease such as RA and systemic JIA. In terms of RA, the anti-IL-6 receptor monoclonal antibody, tocilizumab, is licensed for use in patients with moderate to severe active disease, who have shown inadequate response to at least one synthetic DMARD including methotrexate or after failure of an anti-TNF. In terms of selection choice, the patients who would gain most are the ones with high inflammatory markers and who are symptomatic with fatigue secondary to anaemia.
The success of treatment with tocilizumab is evidenced by ample phase II and III randomised controlled trials and open-label extension studies. Primary endpoints were achieved comparable to those of other biologics, such as TNF inhibitors, abatacept and rituximab. Importantly, deterioration in structural progression was also halted. Combination therapy with methotrexate, at least at the start of the treatment, is still the preferred choice of administration because of better numerical values in the study results in terms of clinical efficacy. Combination with other synthetic sDMARDs such as hydroxychloroquine, sulfasalazine and leflunomide was also effective without notable differences [51, 79] . Combination therapy, however, is associated with an increased risk of elevated transaminases. Hence studies concerning the point at which methotrexate can be tapered down, or remission-type studies concerning the point at which the treatment dose of tocilizumab can be spread out, are of interest.
The ACT-RAY trial showed that switching to monotherapy was non-inferior to combination therapy with methotrexate despite achieving meaningful clinical efficacy and halting structural progression. This is particularly of benefit in the patient who has intolerance or experiences AEs from methotrexate. The recommended dose as monotherapy is 8 mg/kg given every 4 weeks. Various national registries have revealed that about one third of the patients worldwide are on biologic monotherapy [80, 81] . Perhaps this is the strongest selling point of tocilizumab to date: it is one of the few biologics given as a monotherapy that has shown superiority to methotrexate in head-to-head studies [44] . In fact, the ADACTA trial recently revealed clinical superiority of tocilizumab therapy compared to adalimumab monotherapy, although comparison was not done against combination treatment of adalimumab ? methotrexate [82] .
In terms of feasibility, patient preference remains the priority. As it is administered intravenously every 4 weeks, it suits patients adverse to subcutaneous injections of biologic treatment or those who are able to travel to hospital. An advantage of intravenous administration is that blood tests, particularly fasting lipid profiles, at intervals can be monitored more carefully. On the other hand, this also increases the cost of treatment further in terms of staffing resources. Hence, the development of subcutaneous tocilizumab and other IL-6 agents that are currently in phase III trials are eagerly anticipated.
Tolerability and safety data will always be the top priority in a novel treatment of a chronic condition. Although tocilizumab does not have the long-term safety record of the TNF inhibitors, which have been licensed for 13 years, the overall safety data appear comparable [71] . A metaanalysis of the risk of AEs has revealed a small but significant increase in AEs and infections in patients treated with 8 mg/kg of tocilizumab compared with controls. Hence, vigilance is needed particularly when treatment is offered to patients with multiple comorbidities and the elderly population. The rates of SAEs and death were comparable to those of other biologics that are currently available. It is still uncertain whether treatment with tocilizumab can lead to re-activation of tuberculosis or induce demyelinating disease. Until then, patients should be screened for these two conditions as per other biologics prior to starting treatment.
Long-term cardiovascular safety is of major concern in systemic inflammatory disease and patients with rheumatoid arthritis are more likely to have macrovascular complications than the general population [83, 84] . Elevations in liver function tests that followed the 'saw-tooth' pattern between the infusions were frequent in patients receiving tocilizumab in a dose-dependent manner, particularly in combination with methotrexate. So far, data from a 5-year study have shown that the elevated lipid profiles were not associated with an increased risk of major cardiovascular events [48] .
Conclusion
Data from clinical trials and meta-analysis have shown that both the clinical efficacy (even when using a composite index that excludes APRs in the formula such as CDAI) and safety profile of IL-6 blocking agents, notably tocilizumab, are comparable to those of other biologics that are available for use in RA. Longer term studies exploring macrovascular complications, assessment of structural progression using modalities such as ultrasound and MRI, together with the development of IL-6 agents administered subcutaneously over the next few years should make the targeting of IL-6 a mainstay in the treatment of RA.
